Large molecule therapies hold immense promise for treating a range of diseases. However, developing large molecule therapies has unique challenges, particularly in preclinical testing. Toxicology studies are crucial because they provide essential data about the drug’s biological effects and safety profile. While small-molecule drugs have been the cornerstone of pharmaceutical development for decades, large-molecule therapies require different considerations because of their complex structures and modes of action. As drug developers prepare for the Investigational New Drug (IND) process for biologics, they must address several toxicology factors to ensure smooth regulatory approval and efficient development timelines.
Important Components of Toxicology Studies for Large Molecules
Although the core objectives of toxicology studies for small and large molecules are similar, including assessing their safety, pharmacokinetics, and potential toxicity, the requirements and methodologies differ significantly. Many large molecules intended for human use are immunogenic in animals, so when conducting repeat dose studies for these types of products, additional analyses, such as anti-drug antibody (ADA) sampling, are performed in an attempt to aid data interpretation.
Another critical aspect of large molecule toxicology is the selection of the relevant test species. Unlike small molecules, where metabolic similarity to humans is key, large molecule species selection is based on pharmacological relevance. Considerations include:
- Criteria for selecting relevant species: A relevant species is one in which the test material is pharmacologically active due to the expression of the receptor or an epitope (in the case of monoclonal antibodies).
- Challenges in species selection: Many large molecules interact with human-specific receptors or epitopes, limiting the number of suitable laboratory animals. In addition, toxicity studies in non relevant species may be misleading and are discouraged.
- Alternative models: In cases where relevant species are absent in common species, alternative strategies, such as genetically modified mice, surrogate molecules, or human cell-based assays, may be viable options when scientifically justified.
The Challenges of Immunogenicity and/or Immunotoxicity
Immunogenicity is a big concern in large-molecule therapies. The body’s immune response can lead to the formation of ADAs, which may neutralize the drug’s therapeutic effects or cause unintended toxicities. While preclinical immunogenicity assessments do not always translate directly to clinical outcomes, they provide crucial insights into potential immune reactions.
ADA sampling conducted at various times throughout preclinical studies is essential for interpreting toxicology findings. If exposure to the drug declines during a study, it may indicate that ADAs neutralize the drug, which impacts both efficacy and toxicity interpretations. Therefore, integrating ADA analysis into toxicology studies ensures a thorough understanding of the drug’s safety profile.
Drug developers can take several steps to address immunogenicity concerns. They can adjust dosing to reduce immune responses, include immunosuppressive strategies in studies when needed, and use advanced techniques to distinguish immune effects from direct toxicities. These approaches help ensure a clearer understanding of a drug’s safety.
Safety Pharmacology Considerations
Safety pharmacology evaluations, particularly for the central nervous system (CNS), cardiovascular, and respiratory functions, are also critical in large molecule drug development. ICH S6 regulatory guidelines allow for integrating safety pharmacology assessments into toxicology studies and eliminate the need for standalone studies.
- Cardiovascular and respiratory endpoints can be evaluated using jacketed external telemetry (JET) in non-rodents.
- CNS assessments evaluate the effects of drugs, diseases, or injuries on the brain and spinal cord. In rodent studies, these assessments can be conducted using a blind approach to ensure objective evaluations.
This integrated approach minimizes animal use, reduces study costs, streamlines the path to IND submission, and aligns with ethical and regulatory standards.
Formulation and Bioanalytical Analyses: Critical Factors
Formulation analysis ensures a drug’s stability and function in preclinical studies, especially for large molecules. It includes ultraviolet-visible (UV-VIs) spectrophotometry to measure concentration, high-performance liquid chromatography (HPLC) to assess purity and stability, and in vitro binding studies to confirm biological activity by analyzing interactions with specific targets.
Early formulation analysis helps identify potential stability issues before they impact the study, reducing delays and ensuring consistency in toxicology testing.
When compared to small molecules, more robust bioanalytical expertise is required to assess pharmacokinetics/toxicokinetics, ADA as well as immunotoxicity (e.g. cytokines) for large molecule products.
Early Planning and Regulatory Considerations
Engaging with regulatory authorities early in the drug development process is essential to keep your drug development timeline intact and ensure compliance with evolving standards. Key steps include:
- Proactive communication with regulatory agencies to align expectations and clarify study requirements.
- Detailed and well-documented study plans to demonstrate adherence to regulatory guidelines.
- Timely response to regulatory feedback to prevent setbacks in the IND submission process.
Working with experienced laboratory testing partners familiar with large molecule toxicology can provide valuable insights and help navigate complex regulatory landscapes.
A Final Word
Successful toxicology studies for large molecule drugs require careful planning, appropriate species selection, thorough immunogenicity assessments, and robust formulation analysis. By following best practices and engaging regulatory authorities early, drug developers can streamline their IND submissions, minimize risks, and accelerate the development of innovative biologic therapies. By avoiding common pitfalls and leveraging expert partnerships, regulatory approval can be achieved and will ensure that promising therapies reach patients as efficiently and safely as possible.
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”
